Catalog |
name |
Description |
price |
R-Mcs-046 |
DOPG:DOPC:Chol |
DOPG:DOPC:Chol(Adenosine triphosphate Liposomes) can be used for study the biophysical properties of cell membranes.Liposomes formed from these lipids can be used to deliver therapeutic agents.DOPG:DOPC:Chol(Adenosine triphosphate Liposomes) to understand membrane protein interactions, receptor signaling, and cellular processes. |
price> |
R-Mcs-047 |
DOPG:DOPC:Chol (0.5:69.5:30 molar ratio) |
DOPG:DOPC:Chol(Adenosine triphosphate Liposomes) can be used for study the biophysical properties of cell membranes.Liposomes formed from these lipids can be used to deliver therapeutic agents.DOPG:DOPC:Chol(Adenosine triphosphate Liposomes) to understand membrane protein interactions, receptor signaling, and cellular processes. |
price> |
R-Mcs-052 |
DOTAP:DOPC(Liposomes) |
DOTAP:DOPC/1,2-dioleoyl-3-trimethylammonium-propane(chloride salt):1,2-dioleoyl-sn-glycero-3-phosphocholine(Liposomes) is a Cationic Adenosine triphosphate Liposomes.DOTAP:DOPC lipid combination is often used in the design of liposomes for gene therapy. DOTAP facilitates complexation with nucleic acids due to its positive charge, while DOPC helps stabilize the lipid bilayer structure, contributing to the formation of more stable liposomes.DOTAP:DOPC lipid can also encapsulate small molecules or other therapeutics, offering a vehicle for targeted delivery.DOTAP:DOPC lipid can serve as a model system for studying interactions within lipid bilayers, especially for researching how charged and neutral lipids interact and influence membrane properties. |
price> |
R-Mcs-053 |
DOTAP:PC:Chol (10:60:30 molar ratio) |
DOTAP:PC:Chol/1,2-dioleoyl-3-trimethylammonium-propane (chloride salt):L-alpha-Phosphatidylcholine:Cholesterol(10:60:30 molar ratio) used in drug delivery systems. The balance of charge and stability allows for effective delivery vehicles, capable of encapsulating and protecting therapeutic agents.The presence of DOTAP allows for complexation with DNA or RNA, while the structural role of PC ensures the formulation of stable vesicles. Cholesterol further stabilizes these vesicles against physical and chemical stresses, improving their delivery efficiency in biological systems.Researchers might use this mixture to study lipid bilayer characteristics, such as fluidity and phase behavior, or as models for more complex biological membranes. |
price> |
R-Mcs-054 |
PC:Chol (65:35 molar ratio) |
PC:Chol/L-alpha-Phosphatidylcholine:Cholesterol(65:35 molar ratio) is a Neutral Adenosine triphosphate Liposomes.PC:Chol (65:35 molar ratio) can be used to simulate the composition and biophysical properties of natural cell membranes, such as those found in mammalian cells. It provides a balance that closely approximates the fluidity and phase behavior observed in real biological membranes.This mixture is useful for exploring lipid rafts—cholesterol-rich microdomains in cell membranes that are important for cell signaling and protein sorting. The presence of cholesterol in substantial quantities supports the phase separation necessary for raft formation. Liposomes prepared with a 65:35 PC to cholesterol ratio are often used for drug delivery, offering a stable membrane environment for encapsulating hydrophilic or hydrophobic compounds. |
price> |
R-Mcs-055 |
DOPC:DOPE:Chol (50:30:20 molar ratio) |
DOPC:DOPE:Chol (50:30:20 molar ratio) is a Neutral Adenosine triphosphate Liposomes.The DOPC:DOPE:Chol (50:30:20) lipid mixture is highly versatile and tailored for various applications in research, especially in the fields of drug delivery and membrane biology. |
price> |
R-R-5665 |
HSPC/Chol/DSPE-mPEG2000/DSPE-mPEG2000-maleimide (50/45/4/1, mol/mol) Liposomes |
HSPC/Chol/DSPE-mPEG2000/DSPE-mPEG2000-maleimide (50/45/4/1, mol/mol) Liposomes. PEGylated liposomes containing free maleimide functional group for maleimide-thiol conjugation. The liposomes are co-formulated with 1 mol% DSPE-mPEG2000-maleimide, and supplied in a pH-optimized buffer for direct conjugation of the thiol-containing molecule of choice. Conjugation can be achieved by incubating the liposomes with the activated thiol-containing compound which has been reduced by a disulfide bond reducing agent such as (tris(2-carboxyethyl)phosphine) (TCEP), which can be purchased as an add-on. |
price> |
R-R-5666 |
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1 |
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1. PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only. |
price> |
R-R-5667 |
DT-061 (SMAP) Liposomes, Formulation TT-40 |
DT-061 (SMAP) Liposomes, Formulation TT-40. PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only. |
price> |
R-R-5668 |
Liposomes for Loading Hydrophobic Drugs |
Liposomes for Loading Hydrophobic Drugs (5.0mL). This pre-formed liposome product is created for post loading of hydrophobic small molecule compounds into liposomes. The process of drug incorporation is very straight-forward. Then simply add an aliquot of drug solution (prepared in a water-miscible solvent such as ethanol, DMSO and etc.) into the liposome suspension. The drug molecules can be incorporated into the lipid bilayers by the nature of hydrophobic interactions. The drug solubility therefore could be significantly enhanced. Liposomal drug concentration of 1-2 mg/mL could be achieved for most lipophilic drugs. PEGylation of the liposomes provides not only better formulation stability but also the potential of achieving prolonged in vivo blood circulation. The finished drug loaded formulations are suitable for either in vitro testing or in vivo studies. |
price> |